Long-term safety study of RAY121 for immune conditions
Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Eyes & vision, Genetic & congenital, Heart & circulation, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study is for people who already took RAY121 in a previous trial and did well. It tests whether continuing the treatment is safe and effective over a longer period. The goal is to manage chronic immune conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have completed 4 doses of RAY121 in the earlier RAY902CT study and had a good response.
- Must not have had a severe allergic reaction to a biologic medicine in the past.
- Must not have an active infection from capsule-forming bacteria (like pneumococcus).
- Must not have received a live vaccine (e.g., MMR, shingles) in the last 4 weeks.
- Must agree to use highly effective contraception or avoid pregnancy (for women and men) during the study and for 20 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called RAY121 (an antibody) for people with certain autoimmune diseases. It aims to see if RAY121 is safe and how the body handles it. If you have one of these conditions and meet the basic health requirements, you might be able to join.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
This trial tests a new medicine, S-4321, for people with various autoimmune conditions like rheumatoid arthritis, psoriasis, eczema, or lupus. It aims to see if the drug is safe and can help control the overactive immune system.
This study tests an investigational injection called RN1201 for people whose autoimmune disease (like lupus, myasthenia gravis, or immune thrombocytopenia) has not responded to standard therapies. The goal is to see if it can better control the disease.
Hear when a new Antiphospholipid Syndrome (APS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.